Please note that this summary was posted more than 5 years ago. More recent research findings may have been published.
This is a plain English summary of an original research article. The views expressed are those of the author(s) and reviewer(s) at the time of publication.
Low dose aspirin only appears to be effective at preventing stroke or heart attack for people weighing less than 70kg, while higher doses are better for people who weigh over 70kg.
Researchers analysed data from 13 trials of aspirin for primary or secondary prevention of cardiovascular events, totalling over 115,000 participants. They found that 75 to 100mg aspirin only benefitted people who weighed less than 70kg, while only those who weighed 70kg or more benefited from doses of 325mg or above.
This NIHR-funded trial suggests that prescribing the same dose to people of all weights is unlikely to be ideal and, if aspirin is indicated, dose adjustments by weight are required.
UK guidelines do not recommend routine treatment with aspirin for people who do not have cardiovascular disease because of the increased risk of bleeding. However, for people at high risk of heart attack or stroke, the benefits may outweigh this increased risk. This study suggests that the dose may also need to be adjusted according to a person’s weight.
Why was this study needed?
Around 45% of men and 34% of women aged 65 and over in the UK take aspirin to prevent cardiovascular events. Aspirin is recommended as secondary prevention after a heart attack or ischaemic stroke, but its place in primary prevention of cardiovascular disease is less certain and recent large studies have questioned this role.
Studies have shown that an antiplatelet effect may help reduce risk of a first cardiovascular event. However, the effect size is modest and varies in different groups (such as men and women). Aspirin also raises the risk of bleeding and gastrointestinal problems.
The researchers wanted to find out whether overall body weight (not body mass index) affected how much benefit people got from aspirin.
What did this study do?
Researchers carried out a systematic review of individual patient data from randomised trials of aspirin for prevention of cardiovascular disease. Nine trials were aimed at primary prevention, and four looked at secondary prevention after a stroke.
The researchers calculated the effect of different doses of aspirin for people who weigh 70kg or above, or less than 70kg.
The figures were adjusted to take account of factors including people’s age, sex, smoking status, body mass index and whether they used enteric coated or delayed release aspirin.
Some analyses were based on small numbers, and the trials were not set up to compare aspirin effectiveness for people of different weights, but the trends found are plausible.
What did it find?
For primary prevention of any cardiovascular event:
- Low dose aspirin (75 to 100mg) reduced the risk by 23% in men and women weighing less than 70kg (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.68 to 0.87). People weighing 70kg or more did not get any reduction in risk from taking low dose aspirin (HR 0.95, 95% CI 0.86 to 1.04).
- Higher dose aspirin (300 to 325mg) did not reduce the risk for people weighing less than 70kg (HR 1.01, 95% CI 0.79 to 1.30) but reduced the risk by 17% in men and women weighing 70kg or more (HR 0.83, 95% CI 0.70 to 0.98).
For secondary prevention of any cardiovascular event:
- Low dose aspirin was effective for people weighing less than 70kg, reducing the risk by 33% (HR 0.67, 95% CI 0.54 to 0.84) but not for people weighing 70kg or more (HR 1.01, 95% CI 0.75 to 1.37).
- Higher doses of aspirin did not reduce the risk for people weighing less than 70kg (HR 0.95, 95% CI 0.76 to 1.18) but reduced the risk by 27% for people weighing 70 to 79kg (HR 0.73, 95% CI 0.58 to 0.93).
Bleeding risk:
- Both low and high dose aspirin increased the risk of a major bleed at any weight except low dose for people over 90kg.
What does current guidance say on this issue?
NHS guidance does not recommend antiplatelet treatment for the primary prevention of cardiovascular disease because the benefits do not outweigh the risk of intestinal bleeding. However, it does recommend considering aspirin for people at high risk of stroke or myocardial infarction.
Antiplatelet treatment is recommended for secondary prevention of cardiovascular events in people with angina and peripheral arterial disease, acute coronary syndrome and after heart attack, stroke or a stent implant. The recommended dose for aspirin is 75mg a day, and the guidance does not suggest varying this by body weight.
What are the implications?
The findings challenge current guidance and clinical practice in the way aspirin is used to protect against cardiovascular disease. These results suggest that current practice may not be effective for the majority of people, those over 70kg, taking standard low dose aspirin to prevent heart attacks and strokes.
Although the authors of the study propose a weight-based dosing schedule based on their results, this needs to be validated with further research. The results imply that antiplatelet treatment could be improved with weight-based dosing.
Citation and Funding
Rothwell PM, Cook NR, Gaziano JM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387-99.
This project was funded by the National Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust.
Bibliography
K N Theken and T Grosser. Weight-adjusted aspirin for cardiovascular prevention. Lancet. 2018; 392:361-62.
NICE. Antiplatelet treatment. Clinical Knowledge Summary. London: National Institute for Health and Care Excellence; updated June 2018.
P Elwood, G Morgan, J White et al. Aspirin taking in a south Wales county. Br J Cardiol. 2011;18;101-72.
Produced by the University of Southampton and Bazian on behalf of NIHR through the NIHR Dissemination Centre
NIHR Evidence is covered by the creative commons, CC-BY licence. Written content and infographics may be freely reproduced provided that suitable acknowledgement is made. Note, this licence excludes comments and images made by third parties, audiovisual content, and linked content on other websites.
